ArticleBioMed research international2026
Preimplantation Genetic Testing for Aneuploidy Improves Cumulative Live Birth Rate and Reduces Miscarriage in Recurrent Pregnancy Loss.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preimplantation Genetic Testing for Aneuploidy Improves Cumulative Live Birth Rate and Reduces Miscarriage in Recurrent Pregnancy Loss.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRecurrent pregnancy loss (RPL), defined as ≥ 2 consecutive/nonconsecutive losses, affects 1%-5% of pregnant women. This study is aimed at assessing whether preimplantation genetic testing for aneuploidy (PGT-A) improves cumulative live birth rates and reduces miscarriage risk in couples with recurrent pregnancy loss and normal karyotypes undergoing assisted reproduction.
methodsA total of 1039 couples with recurrent pregnancy loss who underwent assisted reproductive treatment were enrolled in this retrospective cohort study between January 2013 and December 2023. Participants were stratified into two groups according to their decision to undergo PGT-A: 200 couples who underwent PGT-A and 839 couples who did not. In total, 670 frozen embryo transfer (FET) cycles were included in the analysis. The clinical characteristics and reproductive outcomes including the cumulative live birth rate were compared between the two groups using different statistical methods.
resultsPGT-A demonstrated significant improvements in reproductive outcomes for women with RPL. In women ≤ 35 years, PGT-A increased the cumulative live birth rate from 51% to 70% (aRR 1.38, 95% CI 1.059-1.82; p = 0.025), whereas in women > 35 years, the rate improved from 21% to 35% (aRR 1.69, 95% CI 1.03-2.77; p = 0.037). Notably, PGT-A also reduced miscarriage rates in younger women, with early miscarriage rates decreasing from 13% to 7% (p = 0.028) and late miscarriages being eliminated (0% vs. 3%, p = 0.017).
conclusionsPreimplantation genetic testing for aneuploidy significantly increased the cumulative live birth rate in couples with recurrent pregnancy loss across both age groups (≤ 35 years and > 35 years) and reduced early and late miscarriage rates in those ≤ 35 years. However, its benefits diminished in patients undergoing fresh embryo transfers, suggesting that the embryo transfer strategy may influence its effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.